B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

SLC22A3

MOLECULAR TARGET

solute carrier family 22 member 3

UniProt: O75751NCBI Gene: 65819 compounds

SLC22A3 (solute carrier family 22 member 3) is targeted by 9 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting SLC22A3

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Corticosterone1.614
2Famotidine1.102
3N-Methylscopolamine1.102
4Progesterone0.691
5Chlorhexidine0.691
6Colchicine0.691
7Desoxycorticosterone0.691
8pentamidine0.691
9thiamine0.691

About SLC22A3 as a Drug Target

SLC22A3 (solute carrier family 22 member 3) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 9 compounds with documented SLC22A3 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

SLC22A3 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.